Top 10 opportunities for licensing

The Institut Pasteur is currently offering 10 major opportunities available for licensing in the fields of diagnostics, therapeutic, vaccines, imaging and enabling technologies.

 

 

  • Hot Topics
    Multiple use of VHH single-domain antibodies: from diagnostics or therapeutic carriers to immunotherapy agents
  • Hot Topics
    A cocktail of to blocking antibodies, targeting human anti-hFgcR mAbs to treat rheumatoid arthritis, inflammation and allergic shock
  • Hot Topics
    ADAM12-expressed in stromal cell as a marker for early stage inflammation
  • SHERPAxMAPTM, an innovative multiplexing technology for improving serodiagnosis
  • Hot Topics
    Diagnostic du mélanome à l’aide du biomarqueur RACK1
  • Hot Topics
    Use of Measle virus to produce recombinant or chimeric replicative vaccines for Influenza or respiratory virus such as RSV
  • Hot Topics
    Use of an HBV recombinant vector to kill HBV-infected hepatocytes
  • Hot Topics
    Enhanced and red-sifted bio-/medical in vivo/vitro optical imaging technique
  • Hot Topics
    New therapeutic neurodegenerative biologicals at early preclinical stage for spinal cord and nerve injuries (SCI), ALS or neurodegenerative diseases through the promotion of neurosurvival pathway
  • Hot Topics
    Structural variants of mycolactone for use in modulating inflammation and pain
Hot Topics

Multiple use of VHH single-domain antibodies: from diagnostics or therapeutic carriers to immunotherapy agents

Patent application title: Variable domains of camelid heavy-chain antibodies directed against glial fibrillary acidic proteins

Inventors: Pierre Lafaye

 

Invention Disclosure: 2007-067 and 2010-032

Key words: camelid single-domain antibodies (VHH), blood-brain barrier, intracellular carrier, neuro-diagnostic imaging, therapeutic use for brain disorders

This technology relates to the use of camelid heavy-chain antibodies (VHH domains) for delivering therapeutic or diagnostic agents across the mammal blood-brain barrier (BBB) and cell membranes.

In particular, we observed that VHHs, conjugated with GFP, were able to pass the BBB, enter into astrocytes and specifically bind to GFAP (Glial Fibrillary Acidic Protein) which is one of the major markers of astrocytes, as well as a crucial marker of gliosis in CNS tumors and degenerative conditions of brain tissues.

These antibodies therefore represent potential neuro-diagnostic imaging agents for brain diseases and  therapeutic agents for brain disorders.

More generally, we are also interested in industrial collaborations to develop other pharmaceutical and biotechnological applications from the VHH technology.

Hot Topics

A cocktail of to blocking antibodies, targeting human anti-hFgcR mAbs to treat rheumatoid arthritis, inflammation and allergic shock

Patent application title: A cocktail of to blocking antibodies, targeting human anti-hFgcR mAbs to treat rheumatoid arthritis, inflammation and allergic shock

Inventors: Pierre Bruhns

 

Invention Disclosure: 2010-036 and 2010-037 and 2012-046

Key words:Therapeutics antibodies, Human Fc receptors, Autoimmunity, Inflammation, Anaphylaxis


​Multiple roles for mFcγRs (IgG receptors) have been reported in vivo without significant results for therapeutics application. New proof of mechanism evidence that expression of hFcγRI or hFcγRIIA was sufficient to induce models of autoimmune arthritis and thrombocytopenia, of immune complex-induced airway inflammation, of active and passive systemic anaphylaxis (allergic shock). Two monoclonal antibodies have been identified, that could block the binding of pathogenic antibodies to hFcγRI or hFcγRIIA. Results unravel two novel therapeutic antibodies that, when used in combination, should prevent the appearance of autoimmune, inflammatory and allergic diseases that rely on pathogenic antibodies, or reduce symptoms when administered after disease outbreak.

Hot Topics

ADAM12-expressed in stromal cell as a marker for early stage inflammation

Invention disclosure title: Adam12 inhibitors and their use against inflammation-induced fibrosis

Inventors: Lucie Peduto


Invention Disclosure: 2009-028

Key words: early inflammation, ADAM12, metalloprotease, stromal cell, specific expression, therapeutic targed

Researchers observed 1) specific expression of ADAM12 (a disintegrin and metalloprotease 12) in injury-activated profibrotic progenitor stromal cells and 2) genetic ablation of ADAM12-expressing cells decreased tissue fibrosis during scarring.  Targeting ADAM12 might represent a new therapeutic approach in inflammatory diseases.

For collaborative research and/or licensing.

SHERPAxMAPTM, an innovative multiplexing technology for improving serodiagnosis

Invention disclosure title: MGMT-based method for obtaining high yield of recombinant protein expression

Inventors: Philippe Desprès

 

Invention Disclosure: 2010-025, 2010-027

Key words: emerging disease, human viral disease, recombinant viral antigens, stable cell line, viral serodiagnosis

The present invention relates to a novel enhancer of protein production in host cells. It discloses a vector for expressing recombinant proteins in these cells, comprising a nucleotide sequence encoding i) a secretion peptidic signal, ii) a 6-methylguanine-DNA-methyltransferase enzyme (MGMT, EC 2.1.63), a mutant or a catalytic domain thereof, and iii) a recombinant protein. Said MGMT enzyme is preferably the so-called SNAP protein.

Hot Topics

Diagnostic du mélanome à l’aide du biomarqueur RACK1

Intitulé de la déclaration d’invention : Régulation positive de RACK1 dans le mélanome et son utilisation comme marqueur

 

Inventeur : Jean-Jacques Panthier

 

Déclaration d’invention : 2007-004

Mots clés : anticorps, dermatologie, marqueur, oncologie, vétérinaire

 

La présente invention concerne une méthode de diagnostic d’un mélanome chez un mammifère, incluant la détection de la surexpression de la protéine RACK1 dans un mélanocyte dudit mammifère et le dépistage d’un mélanome à partir de cette surexpression. L’invention vise également à déterminer le stade tumoral d’un mélanocyte d’un mammifère en détectant la surexpression de la protéine RACK1 dans le mélanocyte, ainsi que le stade tumoral de la cellule à partir de cette surexpression.

Hot Topics

Use of Measle virus to produce recombinant or chimeric replicative vaccines for Influenza or respiratory virus such as RSV

Invention disclosure title: A vaccination vector derived from live attenuated measles vaccine

Inventors: Frédéric Tangy

 

Invention Disclosure: 2002-020

Key words: recombinant, measle-based vaccine, chimeric, Flu, influenza, RSV

A replicating viral vector derived from measles vaccine, one of the safest human live-attenuated vaccines. Constructed from the genomic cDNA of the Schwarz strain of measles virus, this RNA vector is able to express very stably as much as 5 kb of additional genes, either cytoplasmic or membrane proteins.

The new vaccine candidates generated from this vector are intended to be used either in naïve children to simultaneously protect from measles and immunize against other viral antigens (such as HIV, Dengue, malaria…), or in adults as a booster of pre-existing immunity to measles. 

Hot Topics

Use of an HBV recombinant vector to kill HBV-infected hepatocytes

Invention disclosure title: A novel strategy to bypass immune tolerance and to cure infection in HBV

Inventors: Marie-Louise Michel

 

Invention Disclosure: 2007-36

Key words: recombinant, HBV, Hepatitis B, therapeutic vaccine

400 million of people are chronically infected with HBV and more than 1 million die each year from HBV-related liver cirrhosis and hepatocellular carcinoma.

We designed a recombinant HBV vector, derived from the HBV genome, that will express and present foreign antigenic epitopes (derived from common pathogens like flu for instance) at the surface of HBV-infected hepatocytes.

Thus, these epitopes will serve as targets for the T-cells of the immune system which will destroy the HBV-infected cells only. 

Hot Topics

Enhanced and red-sifted bio-/medical in vivo/vitro optical imaging technique

Invention disclosure title: "Method: Excitation of quantum dots by Unbound Bioluminescence Energy Transfer"

Inventors: Spencer Shorte



Invention Disclosure: 2010-005

Key words: medical imaging, optical imaging, bioluminescence, FUEL

(Fluorescence by Unbound Excitation from Luminescence), enhancement, near-infrared

A unique enhanced optical imaging technique based on Bioluminescence Resonance Energy Transfer (BRET) which can be employed to innovative in vivo/in vitro applications in tissue diagnosis, non-invasive detection of bacterial infection, monitoring on small animals and multimodal medical imaging.

For collaborative research and/or licensing.

Hot Topics

New therapeutic neurodegenerative biologicals at early preclinical stage for spinal cord and nerve injuries (SCI), ALS or neurodegenerative diseases through the promotion of neurosurvival pathway

Patent Application title: Viral Polypeptide inducing neuron survival and regeneration, polynucleotides encoding them and therapeutic uses thereof

Inventors: Monique Lafon



Invention Disclosure: 2008-88 and 2011-20

Key words: Peptide, Neuroregeneration, Neurite Outgrowth, Axon Regeneration, Neuroprotection, Regenerative Medicine, Nerve and Spinal Cord Injuries, SCI, ALS, Neurodegenerative Diseases


New neuroprotective intracellular peptides from viral origin with spectacular neuroprotective and neuroregenerative properties. They specifically activate neurosurvival pathways in damaged nerves and degenerating neurons. Mechanism of action, targets and molecular signature of the biomolecules have been described in details.  A proof of concept of efficacy in damaged axons has been obtained in vitro, and the capacity in repairing injured nerves has also been obtained in rat model of peripheral sensory nerve injury. Optimization of a delivery system able to cross blood brain barrier or blood nerve barrier and, to target neurons specifically is now in process. These peptides have also promising potential for restoring or prolonging neuronal plasticity in a large set of neurodegenerative diseases.

 

 

Hot Topics

Structural variants of mycolactone for use in modulating inflammation and pain

Patent application title: Structural variants of mycolactone for use in modulating inflammation and pain

Inventors: Caroline Demangel

 

Invention Disclosure: 2010-15 and 2011-25

Key words: Key words: Molecule, Pain, Inflammation, Autoimmune Disorders

Mycolactone is an original macrolide produced by Mycobacterium ulcerans that blocks the production of chemotactic signals by dendritic cells, suppresses the release of cytokines by macrophages and lymphocytes, and severely impairs T cell homing properties in the mouse model. Patients infected with M. ulcerans, show cellular responses defects at both the local and systemic levels. Cutaneous lesions are painless. This strongly suggests that Mycolactone may also have analgesic properties, possibly dependent on its immunomodulatory effects. Structural variants of natural Mycolactone have been synthesized and retained selectively the immuno-modulatory properties in bioassays. Actually, in vivo assays to evaluate analgesic properties of these variants are in progress. 

Updated on 12/06/2014

donation_form_widget.jpg

Contact & address


Laure Tribout 

Research Applications and Industrial Partnerships Department

Institut Pasteur

28 rue du Docteur Roux

75724 Paris Cedex 15 – France

Document for download

MTA